«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2014年第6期

页码:

666-668

栏目:

临床研究

出版日期:

2014-06-25

文章信息/Info

Title:

Ambrisentan in treatment of pulmonary hypertension after surgery for congenital heart disease

作者:

李艳萍¹; 柳 梅¹; 聂 林²; 徐辉甫¹

(1.武汉市第一医院儿科，湖北 武汉 430000；
2.武汉亚洲心脏病医院ICU，湖北 武汉 430022)

Author(s):

LI Yan-ping¹;  LIU Mei¹;  NIE Lin²;  XU Hui-pu¹

(1.Department of Pediatrics, Wuhan First Hospital, Wuhan 430000, Hubei, China;
2.Cardiovascular Surgery ICU, Wuhan Asia Heart Hospital, Wuhan 430022, Hubei, China)

关键词:

肺动脉高压; 安立生坦; 心脏病; 先天性

Keywords:

pulmonary hypertension;  ambrisentan;  heart disease;  congenital

分类号:

R541.1

DOI:

-

文献标识码:

A

摘要:

目的:评估安立生坦在先天性心脏病术后肺动脉高压中的治疗效果。方法： 我们选取2013年2月~12月70例先天性心脏病术后肺动脉高压的患者。随机分为试药组（n=35）和对照组（n=35）。试药组给予安立生坦+常规治疗，对照组仅给予常规治疗。12周后患者门诊随访，评估心功能状况、行心脏彩超评估肺动脉压力，并化验检测肝肾功能指标。结果： 试药组［(38±5) mmHg vs.(50±6) mmHg,P<0.05］和对照组［(41±6) mmHg vs.(47±7) mmHg,P<0.05］患者术后12周肺动脉压力较术后第3天均明显降低，尽管如此，试药组肺动脉压力降低幅度明显大于对照组［(12±4) mmHg vs.(6±3) mmHg,P<0.05］。试药组患者中30例（86%）心功能明显改善，对照组中25例（71%）心功能明显改善,两者有显著差异（P<0.05）。试药组患者未见肝功能损害及贫血病例。结论： 先天性心脏病术后肺动脉高压的患者使用安立生坦能够安全有效地降低肺动脉压力，改善心功能。

Abstract:

AIM:To evaluate the effect of ambrisentan on pulmonary hypertension after the surgery of congenital heart disease. METHODS: Seventy patients with pulmonary hypertension after surgery for congenital heart disease from February to December 2013 were selected. Patients were randomly divided into experimental group (n=35) and control group (n=35). The experimental group received the combined treatment of ambrisentan and conventional therapy, whereas the control group received conventional therapy only. Outpatient follow-up was conducted in all patients after 12 weeks and cardiac function was assessed by evaluation of pulmonary artery pressure using cardiac ultrasound. Liver and kidney function were also measured. RESULTS: Pulmonary artery pressure in both experimental groups ［(38±5) vs.(50±6) mmHg, P<0.05］ and control group (41±6) vs.(47±7) mmHg, P<0.05］ after 12 weeks significantly decreased compared with the values 3 days after surgery. However, decrease of pulmonary artery pressure in the experimental group was remarkably greater than in the control group ［(12±4) vs.(6±3) mmHg, P<0.05］. More improved cardiac functions were observed in 30 patients in the experimental group (86%) than in 25 patients in the control group (71%). No cases of liver damage and anemia were observed in both groups. CONCLUSION: Application of ambrisentan in patients with pulmonary hypertension after surgery for congenital heart disease is safe and effective in reducing pulmonary artery pressure and improving cardiac functions.

参考文献/References

[1]Engelfriet PM,Duffels MG,M?ller T,et al.Pulmonary arterial hypertension in adults born with a heart septal defect:the Euro Heart Survey on adult congenital heart disease[J].Heart,2007,93(6):682-687.
[2]Apostolopoulou SC,Manginas A,cokkinos DV,et al.Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease:a 2-year study[J].Heart,2007,93(3):350-354.
[3]Van Albada ME,Schoemaker RG,Kemna MS,et al.The role of increased pulmonary blood flow in pulmonary arterial hypertension[J].Eur Respir J, 2005, 26(3):487-493.
[4]Landzberg JM.Congenital heart disease associated pulmonary arterial hypertension[J].Clin Chest Med,2007,28(1):243-253.
[5]Tulloh RM. Congenital heart disease in relation to pulmonary hypertension in paediatric practice[J].Paediatr Respir Rev,2005,6(3):174-180.
[6]Valerio CJ,Coghlan JG.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient[J].Vasc Health Risk Manag,2009,5:607-619.
[7]Huang HQ,Zhang P,Wang Z,et al.Activation of endothelin-1 receptor signaling pathways is associated with neointima formation, neoangiogenesis and irreversible pulmonary artery hypertension in patients with congenital heart disease[J].Circ J,2011,75(6):1463-1471.
[8]Yokoyama Y,Tomatsuri M,Hayashi H,et al.Simultaneous microdetermination of bosentan, ambrisentan, sildenafil,and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension[J].J Pharm Biomed Anal,2014,89:227-232.
[9]Villa G,Morano R,Román A,et al.Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension[J].Farm Hosp,2013,37(5):358-365.
[10]Badesch DB,Feldman J,Keogh A,et al.ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension[J].Cardiovasc Ther,2012,30(2):93-99.
[11]Hartman JC,Brouwer K,Mandagere A,et al.Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes[J].Can J Physiol Pharmac,2010,88(6):682-691.

备注/Memo

备注/Memo:

收稿日期：2014-03-05.通讯作者：柳梅，主治医师，主要从事重症医学研究Email：66799073@qq.com
作者简介：李艳萍，主治医师，硕士Email：66799073@qq.com

常用功能

更新日期/Last Update: 2014-07-10